Empagliflozin Dosing Guidelines

Introduction to Empagliflozin Administration

The American College of Cardiology recommends that empagliflozin tablets should not be broken, split, crushed, or chewed, but rather swallowed whole to ensure proper dosing, drug stability, and bioavailability 1
Breaking film-coated tablets can compromise the protective coating, potentially affecting drug absorption, stability, and gastric tolerability 1

The American Diabetes Association notes that splitting unscored tablets results in unequal dosing, with studies showing dose variations of 15-25% between halves, which is clinically significant for a medication with specific approved doses of 10 mg and 25 mg 2, 1
The approved doses are 10 mg and 25 mg once daily, administered as whole tablets, as recommended by the American College of Cardiology 3, 4, 5, 6

For patients with eGFR ≥60 mL/min/1.73 m², the American College of Cardiology recommends no dose adjustment, with either 10 mg or 25 mg daily 3
For patients with eGFR 45-59 mL/min/1.73 m², the American College of Cardiology recommends not exceeding 100 mg/day (maximum 25 mg dose) 3
For patients with eGFR 30-44 mL/min/1.73 m², empagliflozin maintains cardiovascular benefits but has reduced glycemic efficacy, according to the American College of Cardiology 3
For patients with eGFR <30 mL/min/1.73 m² or dialysis, the American College of Cardiology recommends that empagliflozin is contraindicated 3

For initial therapy, the American Diabetes Association recommends starting with 10 mg once daily 2, 1
For inadequate glycemic control, the American Diabetes Association recommends increasing to 25 mg once daily using the 25 mg tablet 2, 1
For cardiovascular or renal protection, both 10 mg and 25 mg doses demonstrated benefits in the EMPA-REG OUTCOME trial, as noted by the American College of Cardiology 3, 4

The American Diabetes Association recommends never splitting tablets to achieve intermediate doses, as empagliflozin is only available and approved in 10 mg and 25 mg strengths 2
Alternative SGLT2 inhibitors, such as dapagliflozin or canagliflozin, may be considered if empagliflozin dosing options are inadequate 7